Beth Hecht - 03 Aug 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Reporting relationship: Chief Legal Officer and Corporate Secretary
Issuer ticker: XERS
Reported as of: 03 Aug 2026
Net transaction value: -$133,553
SEC form: 4
Accepted by SEC: 04 Aug 2026, 17:16:23 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Beth Hecht

Key filing fact

Beth Hecht filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 04 Aug 2026.

Key facts

This page summarizes Beth Hecht's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Aug 2026, 17:16.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: -$133,553.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001652410 Primary reporting owner

Hecht Beth

Relationship: Chief Legal Officer and Corporate Secretary
Address: C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO
Signature: /s/ Beth Hecht
Signature date: 04 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XERS transaction

Common Stock

Sale

Transaction value: $133,553
Shares: -16,666
Change %: -1.4%
Price: $8.01
Shares after: 1,144,462
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.870 to $8.140, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC remarks

Chief Legal Officer and Corporate Secretary